High Net Worth Advisory Group’s Fate Therapeutics FATE Stock Holding History

High Net Worth Advisory Group’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$10.1K	–	312
2022 Q4	$10.1K	Sell	1,000 -2,500	-71%	-$47K	﹤0.01%	503
2022 Q3	$78K	Hold	3,500	–	–	0.03%	263
2022 Q2	$87K	Hold	3,500	–	–	0.04%	256
2022 Q1	$136K	Hold	3,500	–	–	0.05%	218
2021 Q4	$205K	Buy	+3,500	New	+$198K	0.07%	187

Other funds holding FATE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

High Net Worth Advisory Group's FATE Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 1,000 shares — an estimated $10.1K sold.

High Net Worth Advisory Group first reported a position in FATE in Q4 2021 and held it in 5 quarters. The position peaked at $205K in Q4 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

High Net Worth Advisory Group reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
High Net Worth Advisory Group sold 1,000 Fate Therapeutics shares in Q1 2023, an estimated $10.1K.
High Net Worth Advisory Group first reported a position in Fate Therapeutics in Q4 2021 and held it in 5 quarters.
High Net Worth Advisory Group's Fate Therapeutics position peaked at $205K in Q4 2021.
181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.